Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedMar 20, 2026
DataAggregated Company Financials
Companies5
  • 7D-3.0%
  • 3M-22.7%
  • 1Y-1.6%
  • YTD-20.9%

Over the last 7 days, the Biotech industry has dropped 3.0%, driven by a pullback from Genmab of 5.5%. Meanwhile, Zealand Pharma actually outperformed within the industry, gaining 6.4% in the last week. Over the last year, the industry has been flat overall. Looking forward, earnings are forecast to grow by 1.9% annually.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 21 Mar 2026DKK 135.4bDKK 39.5bDKK 14.0b10.3x9.7x3.4x
Mon, 16 Feb 2026DKK 160.9bDKK 40.3bDKK 18.9b6.1x8.5x4x
Wed, 14 Jan 2026DKK 177.3bDKK 40.8bDKK 19.1b6.4x9.3x4.3x
Fri, 12 Dec 2025DKK 177.5bDKK 40.5bDKK 19.0b6x9.4x4.4x
Sun, 09 Nov 2025DKK 159.1bDKK 40.4bDKK 18.2b10.4x8.7x3.9x
Tue, 07 Oct 2025DKK 185.0bDKK 38.8bDKK 16.8b12.6x11x4.8x
Thu, 04 Sep 2025DKK 158.0bDKK 39.0bDKK 16.8b12.2x9.4x4.1x
Sat, 02 Aug 2025DKK 127.5bDKK 27.2bDKK 7.4b12.7x17.2x4.7x
Mon, 30 Jun 2025DKK 120.1bDKK 26.9bDKK 7.3b10.5x16.4x4.5x
Wed, 28 May 2025DKK 132.3bDKK 27.6bDKK 7.6b10.8x17.5x4.8x
Fri, 25 Apr 2025DKK 126.1bDKK 27.3bDKK 7.7b11.3x16.4x4.6x
Sun, 23 Mar 2025DKK 139.8bDKK 27.3bDKK 7.7b11.9x18.2x5.1x
Tue, 18 Feb 2025DKK 164.7bDKK 27.7bDKK 7.8b12.2x21x5.9x
Thu, 16 Jan 2025DKK 159.6bDKK 26.0bDKK 4.7b16.8x34x6.1x
Sat, 14 Dec 2024DKK 162.7bDKK 26.0bDKK 4.7b16.6x34.7x6.3x
Mon, 11 Nov 2024DKK 178.0bDKK 26.0bDKK 4.3b22.2x41.4x6.8x
Wed, 09 Oct 2024DKK 176.5bDKK 25.5bDKK 5.5b21.3x32.2x6.9x
Fri, 06 Sep 2024DKK 196.5bDKK 25.5bDKK 5.5b23.8x35.9x7.7x
Sun, 04 Aug 2024DKK 199.2bDKK 24.8bDKK 5.6b18.4x35.4x8x
Tue, 02 Jul 2024DKK 188.8bDKK 24.8bDKK 5.6b16.9x33.5x7.6x
Thu, 30 May 2024DKK 176.5bDKK 24.8bDKK 5.6b18.3x31.3x7.1x
Sat, 27 Apr 2024DKK 177.6bDKK 23.9bDKK 5.0b18.5x35.2x7.4x
Mon, 25 Mar 2024DKK 193.4bDKK 23.9bDKK 5.0b19.8x38.5x8.1x
Wed, 21 Feb 2024DKK 174.2bDKK 22.8bDKK 4.2b24.2x41.3x7.7x
Fri, 19 Jan 2024DKK 168.7bDKK 23.3bDKK 4.2b23.5x40.5x7.2x
Sun, 17 Dec 2023DKK 172.6bDKK 23.3bDKK 4.2b25.6x41.5x7.4x
Tue, 14 Nov 2023DKK 175.6bDKK 22.9bDKK 4.5b22.2x38.9x7.7x
Thu, 12 Oct 2023DKK 191.9bDKK 22.0bDKK 4.7b22.2x40.5x8.7x
Sat, 09 Sep 2023DKK 199.3bDKK 22.0bDKK 4.7b23.1x42.2x9x
Mon, 07 Aug 2023DKK 190.2bDKK 20.6bDKK 3.9b36.7x49.1x9.2x
Wed, 05 Jul 2023DKK 200.0bDKK 19.5bDKK 4.4b40.7x45.4x10.2x
Fri, 02 Jun 2023DKK 209.1bDKK 19.5bDKK 4.4b41.2x47.5x10.7x
Sun, 30 Apr 2023DKK 209.6bDKK 17.9bDKK 4.1b32.8x51.2x11.7x
Tue, 28 Mar 2023DKK 196.6bDKK 17.9bDKK 3.5b30.8x55.5x11x
Price to Earnings Ratio

55.5x


Total Market Cap: DKK 196.6bTotal Earnings: DKK 3.5bTotal Revenue: DKK 17.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 30x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 9.7x which is lower than its 3-year average PE of 30.1x.
  • The 3-year average PS ratio of 6.8x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 58% per year over the last three years.
  • Revenues for these companies have grown 30% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-1.73%
Healthcare-3.48%
Biotech-3.03%
Biotech-3.03%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ZEAL Zealand PharmaDKK 287.607.2%
+DKK 1.4b		-49.0%PE3.1x
BAVA Bavarian NordicDKK 190.304.8%
+DKK 670.5m		16.7%PE10.7x
BIOPOR BioPortoDKK 0.911.7%
+DKK 7.4m		-36.6%PS12.3x
STRAP Strategic PartnersDKK 646.000.6%
+DKK 166.8k		-13.9%PB1.5x

Latest News

BIOPOR
DKK 0.91
BioPorto
7D
1.7%
1Y
-36.6%
BAVA
DKK 190.30
Bavarian Nordic
7D
4.8%
1Y
16.7%

BAVA: Expanded Vaccine Partnerships And 2026 Orders Will Support Upside

Analysts have raised their price target on Bavarian Nordic from DKK 265 to about DKK 268, reflecting adjustments to their valuation inputs, including a slightly higher discount rate, a modest change to revenue growth expectations and a marginally different assumed future P/E and profit margin profile. What's in the News Bavarian Nordic expanded its partnership with Serum Institute of India to include full tech transfer and contract manufacturing for the chikungunya vaccine CHIKV VLP, aiming to scale capacity for future supply to endemic low and middle income countries.
GMAB
DKK 1,637.00
Genmab
7D
-3.8%
1Y
20.1%

GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead

Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.
ZEAL
DKK 287.60
Zealand Pharma
7D
7.2%
1Y
-49.0%

ZEAL: Petrelintide Obesity Data And Pipeline Progress Will Support Future Upside

The updated analyst price target for Zealand Pharma moves lower to DKK 611 from about DKK 730, as analysts factor in reduced expectations for petrelintide's obesity opportunity, modestly higher risk assumptions, and a lower implied future P/E multiple, following a series of rating downgrades to Neutral or Hold. Analyst Commentary Recent research notes cluster around a more cautious stance on Zealand Pharma, with several firms shifting ratings to Neutral or Hold and setting price targets below the prior DKK 730 level.
STRAP
DKK 646.00
Strategic Partners
7D
0.6%
1Y
-13.9%